tiprankstipranks
Blueprint Medicines (BPMC)
NASDAQ:BPMC
US Market

Blueprint Medicines (BPMC) Income Statement

Compare
562 Followers

Blueprint Medicines Income Statement

Last quarter (Q4 2024), Blueprint Medicines's total revenue was $146.37M, an increase of 103.41% from the same quarter last year. In Q4, Blueprint Medicines's net income was $-49.96M. See Blueprint Medicines’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 508.82M$ 249.38M$ 204.04M$ 180.08M$ 793.74M
Gross Profit
$ 488.66M$ 236.58M$ 186.22M$ 162.15M$ 793.31M
Operating Expenses
$ 700.71M$ 722.86M$ 723.74M$ 804.13M$ 484.60M
Depreciation and Amortization
$ 16.29M$ 11.66M$ 20.10M$ 12.79M$ 12.35M
EBITDA
$ -212.04M$ -470.36M$ -515.41M$ -628.30M$ 308.71M
Operating Income
$ -212.04M$ -486.28M$ -549.25M$ -648.46M$ 302.15M
Other Income/Expenses
$ 146.18M$ -19.74M$ -14.76M$ 897.00K$ 6.23M
Pretax Income
$ -65.86M$ -506.02M$ -552.28M$ -641.08M$ 314.94M
Net Income
$ -67.09M$ -506.98M$ -557.52M$ -644.09M$ 313.88M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -1.07$ -8.37$ -9.35$ -11.01$ 5.76
Diluted EPS
$ -1.07$ -8.37$ -9.35$ -11.01$ 5.59
Weighted Average Shares Outstanding
62.86M 60.56M 59.64M 58.52M 54.53M
Weighted Average Shares Outstanding (Diluted)
62.86M 60.56M 59.64M 58.52M 56.17M
Currency in USD

Blueprint Medicines Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis